HC Wainwright Reaffirms “Neutral” Rating for Aadi Bioscience (NASDAQ:AADI)
HC Wainwright reaffirmed their neutral rating on shares of Aadi Bioscience (NASDAQ:AADI – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. HC Wainwright also issued estimates for Aadi Bioscience’s Q2 2024 earnings at ($0.66) EPS, Q4 2024 earnings at ($0.71) EPS, FY2024 earnings at ($2.73) EPS, Q1 2025 earnings at […]
More Stories
Wedbush Trims IGM Biosciences (NASDAQ:IGMS) Target Price to $22.00
IGM Biosciences (NASDAQ:IGMS – Free Report) had its price target trimmed by Wedbush from $25.00 to $22.00 in a research...
Oppenheimer Increases Onto Innovation (NYSE:ONTO) Price Target to $275.00
Onto Innovation (NYSE:ONTO – Free Report) had its target price raised by Oppenheimer from $260.00 to $275.00 in a research...
Gritstone bio (NASDAQ:GRTS) Receives Neutral Rating from HC Wainwright
HC Wainwright restated their neutral rating on shares of Gritstone bio (NASDAQ:GRTS – Free Report) in a report published on...
Evercore ISI Raises KeyCorp (NYSE:KEY) Price Target to $20.00
KeyCorp (NYSE:KEY – Free Report) had its target price lifted by Evercore ISI from $18.50 to $20.00 in a report...
JPMorgan Chase & Co. Begins Coverage on Diamondback Energy (NASDAQ:FANG)
JPMorgan Chase & Co. began coverage on shares of Diamondback Energy (NASDAQ:FANG – Free Report) in a research note published...
Deutsche Bank Aktiengesellschaft Increases BWX Technologies (NYSE:BWXT) Price Target to $129.00
BWX Technologies (NYSE:BWXT – Get Free Report) had its target price raised by equities researchers at Deutsche Bank Aktiengesellschaft from...